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its association with volume, inflammatory and endothelial markers in addition to outcome.
33
Eighty-four prevalent hemodialysis patients were evaluated for their plasma syndecan-1 34 levels by ELISA before the start of HD, as well as 60, 180 and 240 minutes after starting 35 dialysis. Patients were divided into sex-stratified tertiles based on predialysis plasma 36 syndecan-1 levels. We studied the association between plasma levels of syndecan-1 and 37 volume, inflammation and endothelial markers and its association with cardiovascular events 38 and all-cause mortality using Kaplan-Meier curves and cox regression analyses with 39 adjustments for gender, age, diabetes and dialysis vintage.
40
Predialysis syndecan-1 levels were two-fold higher in males compared to females 41 (P=0.0003). Patients in the highest predialysis plasma syndecan-1 tertile had a significantly 42 higher ultrafiltration rate (P=0.034) and lower plasma values of BNP (P=0.019), pro-ANP 43 (P=0.024) and endothelin (P<0.0001) compared with the two lower predialysis syndecan-1 44 tertiles. No significant associations with inflammatory markers were found. Cox regression 45 analysis showed that patients in the highest syndecan-1 tertile had significantly less CV 46 events and better survival compared with the lowest syndecan-1 tertile (P=0.02 and P=0.005, 47 respectively).
48
In hemodialysis patients, higher plasma syndecan-1 levels were associated with lower 49 concentrations of BNP, pro-ANP and endothelin, and with better patient survival. This may 50 suggest that control of volume status in hemodialysis patients allows an adaptive tissue 51 regenerative response as reflected by higher plasma syndecan-1 levels.
Introduction 56 Hemodialysis (HD) patients have a strongly increased cardiovascular (CV) mortality rate 57 compared to age-and sex-matched healthy individuals. Various factors contribute to this 58 increased CV mortality, among others uremia, inflammation (1), endothelial dysfunction, 59 hypertension (2), and volume overload (3), all contributing to accelerated atherosclerosis (4).
60
Moreover, HD is an inflammatory trigger and induces oxidative stress (5, 6) and endothelial 61 dysfunction (6, 7) . We hypothesized that in HD patients an adaptive tissue repair response is 62 induced secondary to tissue injury caused by the aforementioned factors related to renal 63 failure including volume overload and by HD-induced inflammation, oxidative stress, and 64 endothelial dysfunction. Syndecan-1 is suggested as a tissue repair response marker. Upon 65 injury, syndecan-1 is upregulated and involved in tissue repair responses in different organs 66 such as the skin (8) or the kidneys (9,10). As a result of cellular shedding, an increase of 67 plasma syndecan-1 levels can be acutely induced by a number of different stimuli such as 68 major surgery, inflammatory insults, ischemia-reperfusion, shock, and also during HD 69 (11, 12) , leading to a lower responsiveness status of the cells of origin. In vitro, syndecan-1 70 shedding can be induced by pro-inflammatory cytokines (13) and a number of growth factors 71 (14) . Syndecan-1 is one of the four transmembrane heparan sulfate proteoglycans (HSPGs) 72 of the syndecan family. All family members contain a transmembrane core protein to which 73 glycosaminoglycan side chains are extracellularly attached (15). Syndecan-1 is expressed in 74 many cell types during development but is down-regulated in most cells after birth (16). In 75 adults, syndecan-1 is mainly expressed by hepatocytes (17), epithelial cells (18) and plasma 76 cells (19) . Elevated plasma syndecan-1 is usually interpreted as endothelial glycocalyx loss, 77 and/or shedding from the (renal) epithelium and/or the liver (9, 20, 21) . Shedding is executed 78 by matrix metalloproteinases (MMPs) and by disintegrin and metalloproteinases (ADAMs), 79 such as MMP9 and ADAM17 (22) . Previous research showed syndecan-1 to be anti-80 apoptotic, anti-inflammatory and anti-fibrotic (9,10).
81
In contrast to acutely-induced syndecan-1 shedding, in chronic disease, tissue 82 syndecan-1 expression reflects an adaptive healing response to the underlying insult, such 83 Running head: Syndecan-1 during hemodialysis.
Page 5 of 21 as renal transplantation (10), heart failure (23), and HD treatment (20) . As such, plasma 84 syndecan-1 levels are believed to reflect tissue expression levels of syndecan-1 as the result 85 of normal turnover (24). However, after initial increase, when damage progressively 86 increases, tissue syndecan-1 expression diminishes again and cell death and fibrosis take 87 over. Various renal models showed reduced repair and more inflammation and fibrosis in 88 syndecan-1 knock-out (KO) mice compared to wild type (WT) animals (10). This is due to its 89 crucial co-receptor function for regenerative growth factors such as vascular endothelial 90 growth factor (VEGF) (25), insulin-like growth factor (IGF) (26), and its association with 91 various integrins (27) . By that, syndecan-1 is orchestrating proliferation (25), migration (28) 92 and adhesion (29). Thus, depending on the stage and severity of the tissue damage, a 93 positive association (initial disease) or a negative association (progressed disease) is found 94 between injury and plasma (or tissue) syndecan-1 (9).
95
Since adaptive tissue repair responses are relevant in the context of HD, the primary study 96 question was whether pre-and intradialytic plasma syndecan-1 levels in stable HD patients 97 associate with volume, inflammatory and endothelial markers and with outcome. This study is a post-hoc analysis of the study by Assa et al. (30) . In short, HD patients from 102 the Dialysis Center Groningen and University Medical Center Groningen were eligible for this 103 study if they were treated with HD for more than 3 months and were on a thrice-weekly HD Patients were studied at the first dialysis session of the week. Dialysis duration was 4 hours.
120
The assessment of patients' characteristics took place at study entry. The definition of 121 diabetes was a fasting blood glucose level of >7 mmol/L or the use of antidiabetic drugs.
122
Hypertension was defined as predialysis systolic blood pressure above 140 mm Hg and/or 123 diastolic blood pressure of higher than 90 mm Hg and/or the use of antihypertensive drugs.
124
We defined cardiovascular history as a history of ischemic heart disease, congestive heart 125 failure, coronary artery bypass grafting, percutaneous coronary intervention, stroke, or 126 Minneapolis, USA). The concentration of all biomarkers that were measured during and after 155 dialysis was corrected for the effect of hemoconcentration according to Schneditz et al. (32) .
156
All stored samples were analyzed at the same time to reduce interassay variability.
157
Laboratory staff was not aware of patient data or outcome. 
Results

179
Patients 180
The characteristics of the 84 patients in this study are shown in Table 1 . One third of the 181 participants were female. The mean (±SD) age of all patients was 63±16 years. Predialysis 182 syndecan-1 levels showed a skewed distribution (Figure 1a ) and were not associated with 183 the underlying disease or the use of medications (data not shown). However syndecan-1 184 levels were found to be two-fold higher in male compared to female patients (P=0.0003) 185 ( Figure 1b ). Therefore, patients were categorized into sex-stratified tertiles according to their 186 plasma syndecan-1 levels, with tertile 1 having low, tertile 2 having intermediate and tertile 3 187 having high syndecan-1 values (Table 1) .
189
Associations with predialysis syndecan-1 190 Age, BMI, body weight, SGA and blood pressure did not differ significantly between 191 syndecan-1 tertiles (Table 1) Running head: Syndecan-1 during hemodialysis.
Page 10 of 21 tertile 3 (hazard ratio for mortality 0.3) had a significantly better survival compared with those 206 in tertile 1 (hazard ratio for mortality 2.1) (P=0.005). For the same adjustments, cox 207 regression also showed significantly lower CV events in tertile 3 (hazard ratio for CV events 208 0.3) compared to tertile 1 (hazard ratio for CV events 1.3) (P=0.02). The major findings of this study are that higher plasma syndecan-1 levels associate with 226 lower plasma levels of BNP, pro-ANP and endothelin, and with higher ultrafiltration rates 227 during HD. Patients in the highest plasma syndecan-1 tertile also had a significantly lower all-228 cause mortality and a lower incidence of CV events.
229
From previous research it is known that dialysis patients have a high incidence of CV 230 events and related mortality (33). This has been linked to uremia, chronic inflammation (1), 231 oxidative stress (5), volume overload (3) 
238
According to our previous observations (9), the syndecan-1 response is bi-phasic 239 upon increasing injury. With initial injury, a tissue repair process is triggered where 240 syndecan-1 plays a role which is reflected by higher tissue as well as plasma syndecan-1 241 values. However, upon progression and chronic development of the underlying damage, 242 cellular syndecan-1 expression is lost again resulting in an inverse association of syndecan-1 243 and disease parameters (9). In many situations, where tissue injury is less severe, a positive 244 association of tissue degradation with syndecan-1 has been reported (10,20). Our research 245 showed that the patients with the highest plasma syndecan-1 values (tertile 3) had better 246 survival and fewer CV events. We therefore consider them to have a better clinical and tissue 247 condition. We could not confirm this by the SGA and inflammatory markers which, however, 248 showed a trend that support our findings. The CRP and IL-6 tended to be lower in tertile 3 249 compared with tertile 1, both before and during HD. Furthermore, we found that the patients Nevertheless, syndecan-1 has been shown to be expressed by hepatocytes (17), epithelial 279 cells (18) and plasma cells (19), but not yet on endothelial cells in vivo (9). Moreover, we 280 could not find significant associations of plasma syndecan-1 with the endothelial markers 281 ICAM-1, von Willebrand factor, Ang1 and 2. We therefore suggest that plasma sydecan-1 282 arises from non-endothelial origin, most likely the liver, epithelial tissues and plasma cells 283 (9, 21) .
284
In this study, we found a significant difference in plasma levels of syndecan-1 285 between men and women. This could be explained by different dietary habits (44) 
